Home > Journals > Minerva Endocrinologica > Past Issues > Minerva Endocrinologica 2015 December;40(4) > Minerva Endocrinologica 2015 December;40(4):321-9

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints
Cite this article as

MINERVA ENDOCRINOLOGICA

A Journal on Endocrine System Diseases


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,383


eTOC

 

REVIEWS  


Minerva Endocrinologica 2015 December;40(4):321-9

Copyright © 2015 EDIZIONI MINERVA MEDICA

language: English

Endocrine manifestations of chronic HCV infection

Caviglia G. P. 1, Rosso C. 1, Fagoonee S. 2, Cisarò F. 3, Andrealli A. 4, Smedile A. 1, 3, Pellicano R. 3

1 Department of Medical Sciences, University of Turin, Turin, Italy; 2 Institute for Biostructures and Bioimages (CNR), c/o Molecular Biotechnology Center, University of Turin, Turin, Italy; 3 Department of Gastroenterology and Hepatology, Molinette Hospital Turin, Italy; 4 Unit of Gastroenterology and Digestive Endoscopy, Valduce Hospital, Como, Italy


PDF  


Chronic hepatitis C virus (HCV) infection has been associated with a great number of extra-hepatic manifestations (EHMs), including several endocrine disorders. Currently available epidemiological, clinical and experimental data do not show a link between HCV and all EHMs. Thyroid disorders (TD) and type 2 diabetes, for example, are the most frequent endocrine alterations in patients with chronic HCV infection, but there are only weak evidences that HCV could be involved in hypothalamic-pituitary axis perturbation, bone metabolism alteration and sexual dysfunctions induction. Thus, this issue needs further investigation. Prospective studies have also shown that interferon (IFN)-based therapy for chronic HCV infection can induce or worsen EHMs. In particular, IFN has been associated with development of autoimmunity and/or TD in up to 40% of chronic HCV infected patients. Hence, a careful monitoring of thyroid function should be performed in such patients. The recent approval of direct-acting antiviral agents in IFN-free regimens for chronic hepatitis C treatment will dramatically reduce not only liver-related mortality but also morbidity due to EHMs.

top of page

Publication History

Cite this article as

Caviglia GP, Rosso C, Fagoonee S, Cisarò F, Andrealli A, Smedile A, et al. Endocrine manifestations of chronic HCV infection. Minerva Endocrinol 2015 December;40(4):321-9. 

Corresponding author e-mail

caviglia.giampi@libero.it